Comparative Pharmacology
Head-to-head clinical analysis: CHLOROPTIC versus MUPIROCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROPTIC versus MUPIROCIN.
CHLOROPTIC vs MUPIROCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloroptic (chloramphenicol) inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, inhibiting protein synthesis.
1 drop (0.5% solution) into the affected eye(s) every 4-6 hours.
Apply a small amount of 2% ointment or cream to affected area three times daily for 5 to 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function, necessitating frequent dosing (every 4-6 hours) to maintain therapeutic levels.
Clinical Note
moderateMupirocin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mupirocin."
Intravenous: ~30 min (0.5 h). Topical: systemically absorbed amount negligible, local half-life not defined.
Primarily renal elimination (70-80% as unchanged drug). Minor biliary/fecal excretion (<10%).
Renal: <1% unchanged (topical); hepatic metabolism to monic acid, eliminated renally and fecally. After IV administration, 60-70% renal, 20-30% fecal/biliary.
Category C
Category A/B
Antibiotic
Antibiotic